Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (603707.SS) has a MoatMap StockRank of 62/100 based on Quality (60/100), Value (48/100), and Momentum (39/100) factor scores. The current signal is HOLD. Nanjing King-Friend is a leading heparin and sterile injectable CDMO with FDA-approved facilities. While it benefits from the CDMO pricing power cycle, it faces geopolitical headwinds from Western supply chain decoupling.
Nanjing King-Friend Biochemical Pharmaceutical is a leading global supplier of heparin sodium active pharmaceutical ingredients (APIs) and a major exporter of finished sterile injectable drugs to highly regulated markets like the US and Europe. The company's competitive moat is sustained by its vertically integrated heparin supply chain and its state-of-the-art FDA-approved manufacturing facilities. It is characterized by its strong regulatory compliance track record and rapid expansion into generic injectable markets globally.
| Price | $1.12 |
| Market Cap | $1.9B |
| P/E (TTM) | 22.31 |
| P/E (Forward) | 16.73 |
| Price/Book | 1.70 |
| Return on Equity | 8.6% |
| Return on Invested Capital | 10.6% |
| Debt/Equity | 38.24 |
| Gross Margin | 38.9% |
| Operating Margin | 10.9% |
| Revenue Growth | 4.9% |
| Dividend Yield | 1.3% |
| Free Cash Flow | $15M |
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).